Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 9/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16609237 | 1.00 | ADRB3 (0.62) | ADRB3ADRB2ADRB1CYP2D6SLC6A4 | |
| SCHEMBL28986806 | 0.88 | ADRB3 (0.68) | ADRB3ADRB2ADRB1CYP2D6SLC6A4 | |
| SCHEMBL28986807 | 0.88 | ADRB3 (0.68) | ADRB3ADRB2ADRB1CYP2D6SLC6A4 | |
| SCHEMBL6621610 | 0.88 | ADRB3 (0.70) | ADRB3ADRB2ADRB1CYP2D6SLC6A4 | |
| SCHEMBL15994158 | 0.88 | ADRB3 (0.70) | ADRB3ADRB2ADRB1CYP2D6SLC6A4 | |
| SCHEMBL16609338 | 0.88 | ADRB3 (0.69) | ADRB3ADRB2ADRB1CYP2D6SLC6A4 | |
| SCHEMBL21952232 | 0.88 | ADRB3 (0.69) | ADRB3ADRB2ADRB1CYP2D6SLC6A4 | |
| SCHEMBL29610257 | 0.82 | ADRB3 (0.58) | ADRB3ADRB2ADRB1CYP2D6SLC6A4 | |
| SCHEMBL25159572 | 0.82 | ADRB3 (0.68) | ADRB3ADRB2ADRB1CYP2D6SLC6A4 | |
| SCHEMBL31361990 | 0.82 | ADRB3 (0.68) | ADRB3ADRB2ADRB1CYP2D6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253005-B2 | Process for the preparation of Mirabegron alpha-form crystals | AUROBINDO PHARMA LTD. (IN) | 2019-04-09 | — | — | US | disclosed |
| US-20180194743-A1 | A process for the preparation of Mirabegron alpha-Form crystals | AUROBINDO PHARMA LTD (IN) | 2018-07-12 | — | — | US | disclosed |
| US-20180194743-A1 | A process for the preparation of Mirabegron alpha-Form crystals | AUROBINDO PHARMA LTD (IN) | 2018-07-12 | — | — | US | disclosed |
| WO-2015162536-A1 | NOVEL PROCESS FOR PREPARATION OF MIRABEGRON AND IT'S INTERMEDIATE | CALYX CHEMICALS AND PHARMACEUTICALS LTD. (IN) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253005-B2 | Process for the preparation of Mirabegron alpha-form crystals | GCGR, GLP1R, ADRB1 | ADRB3 4/4885ADRB2 11/4885ADRB1 3/4885 |
| US-20180194743-A1 | A process for the preparation of Mirabegron alpha-Form crystals | ADRB3, GCGR, ADRB1 | ADRB3 1/4885ADRB2 11/4885ADRB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.